ads

Saturday, October 2, 2021

Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy

Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC).

from News Medical Medical Research News Feed https://ift.tt/3uxHUJI https://ift.tt/eA8V8J


from TechCrunch https://ift.tt/2Y8UAKQ
via IFTTT
at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Apple Vision Pro: Day One

It’s Friday, February 2, 2024. Today is the day. You’ve been eyeing the Vision Pro since Tim Cook stepped onstage with the product at last y...

  • RIP to FTX?
    Image Credits: TechCrunch We had to talk about the news that rocked the crypto world this week in our  Thursday episode :  the Binance/...
  • Fintechs go shopping
    Welcome back to The Interchange, where we take a look at the hottest fintech news of the previous week. If you want to receive The Interchan...
  • Max Q: Galactic
    Hello and welcome back to Max Q! Happy Memorial Day everyone. In this issue: Astranis’ novel approach to GEO satellites Virgin Galactic’...